ArticleCureus2024
Low-Dose Acyclovir Reduces the Reactivation of Herpes Simplex and Varicella Zoster Viruses After Allogeneic Stem Cell Transplantation.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionReactivation of herpes simplex virus (HSV) and varicella zoster virus (VZV) is a potential complication following allogeneic stem cell transplantation (alloSCT). Since different doses and durations of acyclovir prophylaxis may be utilized across transplant centers, this study aimed to evaluate the effectiveness of a lower dose of acyclovir in preventing HSV and VZV reactivation in alloSCT recipients within our institution.
methodsA retrospective chart review was conducted for patients who underwent alloSCT between April 2016 and May 2023. Patients received acyclovir 400 mg orally twice daily as prophylaxis, starting before stem cell infusion and continuing for two years after alloSCT, with ongoing use while on immunosuppressive therapies. Outcomes measured include incidence of HSV and VZV reactivation, timing of viral reactivation, acyclovir-related adverse events, and hospitalizations due to viral reactivation. Pertinent data collected were risk factors for viral reactivation in patients such as immunosuppressive therapies and chemotherapy regimens. Descriptive statistics were used for data analysis.
resultsA total of 246 patients were included in this study. The majority of patients were male with a median age of 60 years (range 20-76) and a diagnosis of acute myeloid leukemia. HSV reactivation occurred in 10 out of the 246 patients (4%) and none had VZV reactivation. The median time to HSV reactivation was 100 days (range 10-1400). No patient had acyclovir-related adverse events such as acute kidney injury, neurotoxicity, or rash. Hospitalization related to HSV reactivation occurred in four of the 10 affected patients (40%).
conclusionsOral acyclovir 400 mg taken twice daily for prophylaxis in alloSCT recipients is both effective and well-tolerated. This lower-dose regimen effectively prevents HSV and VZV reactivation without compromising efficacy or patient safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.